RxDoctor Payments DataLook up a doctor →

David Tschopp, MD

Clinical Cardiac Electrophysiology · Austin, TXNPI 1285679431

Payments from drug & device makers

$406,542in general payments, 2019–2025

Across 1,455 payments — averaging $279.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$257K
  • Medtronic$92K
  • Abbott$33K
  • Biosense Webster, Inc.$7K
  • Boston Scientific$5K
  • E.r. Squibb & Sons, L.L.C.$5K
  • plus $9K from 22 others
$8,657in research payments, 2019–2025

Across 1 payment — averaging $8656.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Atricure, Inc.$9K

What the payments were for

  • Consulting fees$37,05033%
  • Speaking & faculty fees$8,3507%
  • Travel & lodging$15,02013%
  • Food & beverage$49,29643%
  • Other$3,8583%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$406,542 in reported general payments places this provider in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$570,114
Medicare patients
1,180
Services billed
7,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban881$920,820
XareltoRivaroxaban125$155,738
MultaqDronedarone Hcl121$137,877
Dofetilide103$15,625
Flecainide Acetate433$13,743
Dabigatran EtexilateDabigatran Etexilate Mesylate19$6,126
Metoprolol Succinate351$5,560
Diltiazem 24hr Er (Cd)Diltiazem Hcl112$2,714
Mexiletine Hcl30$2,583
SotalolSotalol Hcl154$2,473
ClopidogrelClopidogrel Bisulfate87$1,408
Amiodarone Hcl62$1,199
Digoxin43$717
Propafenone Hcl14$472
Metoprolol Tartrate57$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$4,545$920,820881 claims
Johnson & JohnsonXarelto$1,636$155,738125 claims
Sanofi-aventis U.S. LLCMultaq$549$137,877121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →